Clinical evidence can establish that a product deserves serious attention. It does not automatically complete the implementation, governance, security, financial and organisational decision that follows.
A strong study is not the whole decision
Healthcare AI companies are often told to produce more evidence. That advice is reasonable when clinical validity, safety or performance remain weak. But a company can also reach a different problem: the evidence is serious, the product appears credible, and the buying organisation still cannot confidently advance.
This does not mean the evidence failed. It means the evidence answered only part of a larger decision. A clinical leader may understand the reported result while an operations lead still cannot see the new workflow, a security team still needs the data flow, finance still needs a bounded value case, and the internal champion still has to connect all of those views into one defensible recommendation.
The FDA transparency principles make this distinction visible. They call for information about intended use, users, workflow, performance, benefits, risks, limitations, lifecycle monitoring and the needs of different audiences. The important point is not simply that more information is desirable. Different people need different information at different moments in order to make informed decisions.
Evidence availability is not evidence usability
A case study, technical page, security document and regulatory statement may all exist. Yet the buyer may still need to find them across separate routes, interpret unfamiliar language, reconcile different claims and explain the result to colleagues. The evidence is available, but the decision work remains with the buyer.
Archoric calls this the difference between evidence presence and decision usability. A document becomes decision support only when the relevant stakeholder can find it, understand what it establishes, recognise its limits and know what to do next.
This is why adding another general case study can have less value than creating a clear route through evidence that already exists. The problem may not be evidence quantity. It may be sequencing, audience fit, access or translation.
The buyer is evaluating a transition
A performance result describes what the product can do under stated conditions. The buying organisation must also evaluate what it will take to make that result operational. That includes workflow change, integration, training, oversight, monitoring, exception handling and accountability.
The FAIR-AI framework and other healthcare implementation research emphasise multistakeholder review before implementation and continued monitoring after deployment. This reflects a practical reality: a technically credible product can still be difficult to implement responsibly.
The relevant question is therefore not only, "Does it work?" It is also, "Can our organisation introduce, govern and sustain it under our conditions?"
A useful evidence route
Clinical claim -> intended population and setting -> workflow role -> implementation conditions -> governance and monitoring -> local validation -> decision gate.
Each step changes what the buyer can responsibly conclude. Skipping a step does not necessarily stop interest. It often transfers the missing work to the champion, who must request another document, schedule another meeting or make an assumption.
What companies can do
First, map every major public claim to the stakeholder decisions it is expected to support. Second, state clearly what the evidence establishes and what it does not. Third, show where public orientation ends and controlled diligence begins. Fourth, build purpose-specific routes for clinical, technical, operational, security and commercial questions. Fifth, equip the internal champion with a concise pack that preserves source links, boundaries and open questions.
This does not guarantee a sale or shorten every evaluation. Budget, product fit, organisational priority and procurement constraints may still determine the outcome. The goal is more disciplined: reduce avoidable decision work and make the remaining uncertainty explicit.
The Archoric perspective
The buyer’s problem may be less about trusting the supplier and more about trusting their own ability to make a complex decision. Strong evidence supports that ability only when it is organised around the work the buying group must complete.
The Proof-to-Decision™ Assessment identifies where public evidence supports or fails that work. The Decision Evidence Navigator™ is designed to turn validated findings into a stakeholder-specific decision environment.
Sources
- UK Government, A buyer's guide to AI in health and care
- FDA, Transparency for Machine Learning-Enabled Medical Devices: Guiding Principles
- NIST, AI Risk Management Framework
- WHO, Ethics and governance of artificial intelligence for health
- FAIR-AI, A practical framework for appropriate implementation and review of AI in healthcare
- Early pipeline framework for assessing vendor AI solutions to support return on investment
- DECIDE-AI reporting guideline
- ONC HTI-1 Final Rule
- HHS Healthcare and Public Health Cybersecurity Performance Goals
- FDA, Cybersecurity in Medical Devices: Quality System Considerations and Content of Premarket Submissions
- LinkedIn and Bain, The Principles of Buyability
- Forrester, 2026 State of Business Buying
What does your public evidence currently enable stakeholders to understand?
The Proof-to-Decision™ Assessment applies a governed review to the company’s actual evidence, stakeholder questions and public routes.
Explore the Assessment